Life‐threatening pneumonitis after first‐line treatment with osimertinib for primary T790M mutated non‐small cell lung cancer

Epithelial growth factor receptor (EGFR) directed tyrosine kinase inhibitor (TKI) treatment is the standard approach in patients with advanced, EGFR‐mutated non‐small cell lung cancer (NSCLC). Although benefit/risk ratio is favorable for these TKI and side effects are manageable in the vast majority...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Maik Häntschel, Johannes Niebling, Almut Häring, Max‐Felix Häring, Thorben Groß, Marius Horger, Reimer Riessen, Michael Haap, Richard A Lewis, Michael Böckeler, Jürgen Hetzel
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Wiley 2020-07-01
Цуврал:	Thoracic Cancer
Нөхцлүүд:	Epithelial growth factor receptor interstitial lung disease side effect pneumonitis tyrosine kinase inhibitor
Онлайн хандалт:	https://doi.org/10.1111/1759-7714.13476
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!